Combined Activity of Azithromycin and Lansoprazole Against Helicobacter pylori

Abstract

In the majority of strains, lansoprazole and azithromycin interacted in an additive or synergistic manner depending on the test method employed. Addition of lansoprazole restored in vitro sensitivity to azithromycin in 3 out of 9 azithromycin-resistant strains. Such effects may enhance the elimination of H. pylori during clinical eradication therapy.

A Randomized Controlled Trial: Efficacy and Safety of Azithromycin, Ofloxacin, Bismuth, and Omeprazole Compared With Amoxicillin, Clarithromycin, Bismuth, and Omeprazole as Second‐Line Therapy in Patients With Helicobacter pylori Infection

“…It has been used as the clarithromycin substitute achieving an eradication rate of 72–88%. Unfortunately, clarithromycin‐resistant H. pylori strains may show a cross‐resistance to azithromycin [21]; however, the strong synergistic effect between azithromycin and PPIs may increase eradication rates even with macrolide‐resistant bacteria [22], and primary azithromycin‐resistance has been reported in 10–27% of cases in children [23,24]. Also, the pharmacokinetic characteristics of azithromycin [25] can provide an effective treatment and favor the patients’ compliance.…”